COMPANY

Marker Therapeutics, Inc.

HQ: Houston, TX source · markertherapeutics.com ↗ · Southwest

Keywords: oncology blood cancers solid tumors Relapsed Non-Hodgkin Lymphoma Adult Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Non Hodgkin Lymphoma Hodgkin Lymphoma Adult Hodgkin Lymphoma Hodgkin's Lymphoma, Relapsed, Adult Pancreas Cancer Pancreatic Cancer Metastatic Pancreatic Cancer (Unresectable) Acute Myeloid Leukemia Stem Cell Transplantation Platinum Sensitive Ovarian Cancer Ovarian Cancer Respiratory Failure ARDS Breast Cancer metastatic pancreatic cancer pancreatic cancer MT-601 MT-401-OTS MT-401 Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)

Location: Houston, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

$16.1MRaised (2 yrs)7Trials (company is sponsor)7NIH grants

Funding and NIH signals

NIH award NIH awarded $645K (NIH grant 1R01FD008756-01, new, notice Sep 24, 2026); 2 NIH awards totaling $1.31M in the last 12 months. NIH RePORTER 1R01FD008756-01 (Sep 24, 2026)
Evidence (2 events)
- Sep 24, 2026 · NIH RePORTER 1R01FD008756-01
  Organization: MARKER THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 1R01FD008756-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-24; FY total cost (award amount): 645493; Administering IC: Food and Drug Administration; Project title: Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients; Organization type: Domestic For-Profits
- Jul 20, 2026 · NIH RePORTER 5R44CA291521-03
  Organization: MARKER THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 5R44CA291521-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 665000; Administering IC: National Cancer Institute; Project title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 24, 2026 Grant Government grant — NIH R01: $645,493 (annual award, as published), announced Sep 24, 2026. Agency: NIH/FDA. Source: government award database. source ↗
Aug 15, 2026 Grant Government grant: $4.17M (total, as published), announced Aug 15, 2026. Agency: DoD. Source: government award database. source ↗
Jul 20, 2026 Grant Government grant — SBIR: $665,000 (annual award, as published), announced Jul 20, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Jul 16, 2026 Trial start Phase 1: MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer source ↗
Aug 21, 2025 Grant Government grant — SBIR: $674,275 (annual award, as published), announced Aug 21, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jul 25, 2025 Grant Government grant — SBIR: $664,838 (annual award, as published), announced Jul 25, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jul 16, 2025 Grant Government grant — SBIR: $665,000 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jun 25, 2025 Grant Government grant — NIH R01: $188,702 (annual award, as published), announced Jun 25, 2025. Agency: NIH/FDA. Source: government award database. source ↗
Jun 16, 2025 Trial start Phase 1: Safety of MT-401-OTS in Patients With Relapsed AML or MDS source ↗
May 7, 2025 Grant Government grant — SBIR: $1.35M (annual award, as published), announced May 7, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Dec 19, 2024 Raise Private placement: $16.1M (total, as published), announced Dec 19, 2024. Source: company release on GlobeNewswire. source ↗
Dec 17, 2024 Grant Government grant: $9.5M (total, as published), announced Dec 17, 2024. Source: company release on GlobeNewswire. source ↗
Jan 2, 2023 Trial start Phase 1: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma source ↗
Oct 14, 2020 Trial start Phase 2: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant source ↗
May 20, 2020 Trial start Not phased (device or behavioral study): Plasma Adsorption in Patients With Confirmed COVID-19 source ↗
Jul 20, 2017 Trial start Phase 2: Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer source ↗
2016-04 Trial start Phase 2: Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer source ↗

Upcoming milestones

Feb 28, 2028 (ESTIMATED) · Phase 1 · Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma · NCT05798897
Jul 16, 2028 (ESTIMATED) · Phase 1 · MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer · NCT06549751
2029-09 (ESTIMATED) · Phase 1 · Safety of MT-401-OTS in Patients With Relapsed AML or MDS · NCT06552416

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $16.1M. Last 2 years.

Dec 19, 2024 Private placement: $16.1M (total, as published), announced Dec 19, 2024. Source: company release on GlobeNewswire. source ↗
Sep 24, 2026 Government grant — NIH R01: $645,493 (annual award, as published), announced Sep 24, 2026. Agency: NIH/FDA. Source: government award database. source ↗
Aug 15, 2026 Government grant: $4.17M (total, as published), announced Aug 15, 2026. Agency: DoD. Source: government award database. source ↗
Jul 20, 2026 Government grant — SBIR: $665,000 (annual award, as published), announced Jul 20, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Aug 21, 2025 Government grant — SBIR: $674,275 (annual award, as published), announced Aug 21, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jul 25, 2025 Government grant — SBIR: $664,838 (annual award, as published), announced Jul 25, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jul 16, 2025 Government grant — SBIR: $665,000 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jun 25, 2025 Government grant — NIH R01: $188,702 (annual award, as published), announced Jun 25, 2025. Agency: NIH/FDA. Source: government award database. source ↗
May 7, 2025 Government grant — SBIR: $1.35M (annual award, as published), announced May 7, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Dec 17, 2024 Government grant: $9.5M (total, as published), announced Dec 17, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05798897	Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma	Phase 1	Recruiting	Jan 2, 2023	Feb 28, 2028 (estimated)
NCT06549751	MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer	Phase 1	Not yet recruiting	Jul 16, 2026	Jul 16, 2028 (estimated)
NCT06552416	Safety of MT-401-OTS in Patients With Relapsed AML or MDS	Phase 1	Recruiting	Jun 16, 2025	2029-09 (estimated)
NCT04511130	Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant	Phase 2	Terminated	Oct 14, 2020	Mar 1, 2024 (actual)
NCT02978222	Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer	Phase 2	Terminated	Jul 20, 2017	Jan 15, 2020 (actual)
NCT04358003	Plasma Adsorption in Patients With Confirmed COVID-19	Not phased (device or behavioral study)	Completed	May 20, 2020	Nov 26, 2021 (actual)
NCT02593227	Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer	Phase 2	Completed	2016-04	Jul 15, 2021 (actual)

NIH awards 7

Annual award amounts. Total $4.4M.

Sep 2, 2024 NIH award 5R44CA285177-02 FY2024: $664,838 awarded for that fiscal year; activity R44 (SBIR); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. Phase 2 clinical trial of a novel T source ↗
Aug 30, 2024 NIH award 1R44CA295168-01 FY2024: $674,275 awarded for that fiscal year; activity R44 (SBIR); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. A Phase 1 Study of Patient-Derived M source ↗
Aug 8, 2024 NIH award 1R44CA291521-01 FY2024: $665,000 awarded for that fiscal year; activity R44 (SBIR); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. A Phase 1 Study of Patient-Derived M source ↗
Jun 14, 2024 NIH award 1R44CA287653-01A1 FY2024: $650,671 awarded for that fiscal year; activity R44 (SBIR); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. Controlling Tumor Immune Escape in source ↗
Feb 21, 2024 NIH award 5R01FD007272-02 FY2024: $519,750 awarded for that fiscal year; activity R01 (OTHER_NIH); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. Efficacy of a Multi-Tumor-Assoc source ↗
Aug 8, 2023 NIH award 1R44CA285177-01 FY2023: $664,838 awarded for that fiscal year; activity R44 (SBIR); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. Phase 2 clinical trial of a novel T source ↗
Sep 8, 2022 NIH award 1R01FD007272-01A1 FY2022: $519,750 awarded for that fiscal year; activity R01 (OTHER_NIH); PI VERA, JUAN FERNANDO; recipient as written: MARKER THERAPEUTICS, INC., HOUSTON, TX. Efficacy of a Multi-Tumor-Ass source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-12-30 Raise Private raise (SEC Form D): $16.1M sold; issuer “Marker Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗